240 related articles for article (PubMed ID: 15084239)
21. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression.
Hutchinson J; Jin J; Cardiff RD; Woodgett JR; Muller WJ
Mol Cell Biol; 2001 Mar; 21(6):2203-12. PubMed ID: 11238953
[TBL] [Abstract][Full Text] [Related]
22. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
23. Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.
Natasha T; Kuhn M; Kelly O; Rittling SR
Am J Pathol; 2006 Feb; 168(2):551-61. PubMed ID: 16436669
[TBL] [Abstract][Full Text] [Related]
24. Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation.
Ariztia EV; Subbarao V; Solt DB; Rademaker AW; Iyer AP; Oltvai ZN
Exp Cell Res; 2003 Aug; 288(2):257-67. PubMed ID: 12915117
[TBL] [Abstract][Full Text] [Related]
25. Polyomavirus middle T antigen induces the transcription of osteopontin, a gene important for the migration of transformed cells.
Whalen KA; Weber GF; Benjamin TL; Schaffhausen BS
J Virol; 2008 May; 82(10):4946-54. PubMed ID: 18337582
[TBL] [Abstract][Full Text] [Related]
26. Osteopontin expression in mammary gland development and tumorigenesis.
Rittling SR; Novick KE
Cell Growth Differ; 1997 Oct; 8(10):1061-9. PubMed ID: 9342184
[TBL] [Abstract][Full Text] [Related]
27. Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines.
Morris VL; Tuck AB; Wilson SM; Percy D; Chambers AF
Clin Exp Metastasis; 1993 Jan; 11(1):103-12. PubMed ID: 8422701
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional regulation of human osteopontin promoter by C/EBPalpha and AML-1 in metastatic cancer cells.
Liu YN; Kang BB; Chen JH
Oncogene; 2004 Jan; 23(1):278-88. PubMed ID: 14712233
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA.
Chen RX; Xia YH; Xue TC; Zhang H; Ye SL
Oncol Rep; 2011 Mar; 25(3):803-8. PubMed ID: 21174062
[TBL] [Abstract][Full Text] [Related]
30. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis.
Wai PY; Mi Z; Guo H; Sarraf-Yazdi S; Gao C; Wei J; Marroquin CE; Clary B; Kuo PC
Carcinogenesis; 2005 Apr; 26(4):741-51. PubMed ID: 15661802
[TBL] [Abstract][Full Text] [Related]
31. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype.
Sung V; Gilles C; Murray A; Clarke R; Aaron AD; Azumi N; Thompson EW
Exp Cell Res; 1998 Jun; 241(2):273-84. PubMed ID: 9637769
[TBL] [Abstract][Full Text] [Related]
32. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.
Beausoleil MS; Schulze EB; Goodale D; Postenka CO; Allan AL
BMC Cancer; 2011 Jan; 11():25. PubMed ID: 21247495
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter.
Denhardt DT; Mistretta D; Chambers AF; Krishna S; Porter JF; Raghuram S; Rittling SR
Clin Exp Metastasis; 2003; 20(1):77-84. PubMed ID: 12650610
[TBL] [Abstract][Full Text] [Related]
34. Identification of promoter regions involved in cell- and developmental stage-specific osteopontin expression in bone, kidney, placenta, and mammary gland: an analysis of transgenic mice.
Higashibata Y; Sakuma T; Kawahata H; Fujihara S; Moriyama K; Okada A; Yasui T; Kohri K; Kitamura Y; Nomura S
J Bone Miner Res; 2004 Jan; 19(1):78-88. PubMed ID: 14753740
[TBL] [Abstract][Full Text] [Related]
35. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene.
Wu Y; Denhardt DT; Rittling SR
Br J Cancer; 2000 Jul; 83(2):156-63. PubMed ID: 10901364
[TBL] [Abstract][Full Text] [Related]
36. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.
Gardner HA; Berse B; Senger DR
Oncogene; 1994 Aug; 9(8):2321-6. PubMed ID: 8036014
[TBL] [Abstract][Full Text] [Related]
37. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
38. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency.
Feng F; Rittling SR
Breast Cancer Res Treat; 2000 Sep; 63(1):71-9. PubMed ID: 11079161
[TBL] [Abstract][Full Text] [Related]
39. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors.
Roussos ET; Wang Y; Wyckoff JB; Sellers RS; Wang W; Li J; Pollard JW; Gertler FB; Condeelis JS
Breast Cancer Res; 2010; 12(6):R101. PubMed ID: 21108830
[TBL] [Abstract][Full Text] [Related]
40. An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo.
Ito T; Hashimoto Y; Tanaka E; Kan T; Tsunoda S; Sato F; Higashiyama M; Okumura T; Shimada Y
Clin Cancer Res; 2006 Feb; 12(4):1308-16. PubMed ID: 16489088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
